NZ712814A - Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate - Google Patents

Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate

Info

Publication number
NZ712814A
NZ712814A NZ712814A NZ71281411A NZ712814A NZ 712814 A NZ712814 A NZ 712814A NZ 712814 A NZ712814 A NZ 712814A NZ 71281411 A NZ71281411 A NZ 71281411A NZ 712814 A NZ712814 A NZ 712814A
Authority
NZ
New Zealand
Prior art keywords
acid
diquafosol
ophthalmic solution
producing
same
Prior art date
Application number
NZ712814A
Inventor
Akiko Sakatani
Tatsuo Ikei
Koji Inagaki
Masaki Sonoda
Yoko Fukui
Mitsuaki Kuwano
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of NZ712814A publication Critical patent/NZ712814A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided is an ophthalmic solution comprising diquafosol (P1, P4-di(uridine-5’)tetraphosphate) at a concentration of 0.1 to 10%(w/v) and a chelating agent. Preferred chelating agents include edetic acid, citric acid, metaphosphoric acid, pyrophosphoric acid, polyphosphoric acid, malic acid, tartaric acid and phytic acid. The purpose of the chelating agent is to inhibit the formation of insoluble precipitates in the solution. Further provided is a method for inhibiting the formation of insoluble precipitates in a diquafosol solution by adding a chelating agent.
NZ712814A 2010-12-28 2011-12-27 Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate NZ712814A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010291463 2010-12-28
NZ61252011 2011-12-27

Publications (1)

Publication Number Publication Date
NZ712814A true NZ712814A (en) 2016-08-26

Family

ID=56800425

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ712814A NZ712814A (en) 2010-12-28 2011-12-27 Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate

Country Status (1)

Country Link
NZ (1) NZ712814A (en)

Similar Documents

Publication Publication Date Title
MX2019001253A (en) Protein-active agent conjugates and method for preparing the same.
SG10201811175WA (en) Method for treating cancer using a combination of chk1 and atr inhibitors
UA113839C2 (en) EYE SOLUTION CONTAINING DICVAFOSOL, METHOD OF ITS PREPARATION AND METHOD OF INHIBITION OF NON-SOLUTION DEPOSIT
IN2012DN04940A (en)
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MX2013011854A (en) Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent.
MX2012004210A (en) Pyrazole derivatives as modulators of calcium release -activated calcium channel.
UA115532C2 (en) Hydrazide containing nuclear transport modulators and uses thereof
UA106054C2 (en) Normal;heading 1;heading 2;heading 3;SUBSTITUTED IMIDAZO[1,5-a]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS
MX2011008221A (en) Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor.
MX350112B (en) Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors.
MX2009005413A (en) Crystalline forms of zoledronic acid.
MX2014003376A (en) Benzoic acid derivatives as eif4e inhibitors.
MX2014004646A (en) Method for inhibition of deubiquitinating activity.
GB2500128A (en) Colonoscopy-preparation
MX359318B (en) Compositions comprising peg and ascorbate.
MX2022002219A (en) Triazolopyrimidines as a2a / a2b inhibitors.
NZ610378A (en) Lipoyl compounds and their use for treating ischemic injury
CL2012001300A1 (en) Process for preparing a compound of formula (i) in ionic salt form, comprising the steps of i) hydrogenating a compound of formula (ii) using a metallic catalyst with hydrogen and ii) filtering the catalyst followed by treatment with a solution acid or gas.
PH12016500913A1 (en) Soap bar
IN2014MN01495A (en)
NZ712814A (en) Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
MY181555A (en) 5?-dibenzyl phosphates of 5-azacytidine or 2?-deoxy-5-azacytidine
MX2014005399A (en) Methods for treating gout in patient subpopulations.
MX2015017864A (en) Preparation method for pyrrolidine-2-carboxylic acid derivatives.

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE FILED DATE HAS BEEN CORRECTED TO 27/12/2011

Effective date: 20151002

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 DEC 2018 BY HENRY HUGHES IP LIMITED

Effective date: 20170109

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2019 BY CPA GLOBAL

Effective date: 20181115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2020 BY CPA GLOBAL

Effective date: 20191114

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2021 BY CPA GLOBAL

Effective date: 20201112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2022 BY CPA GLOBAL

Effective date: 20211111

LAPS Patent lapsed